The contagions by Coronavirus have dropped by 24.39% in the last seven days, while the 14-day accumulated incidence is on Thursday at 71.86 for every one hundred thousand inhabitants, three points less than Wednesday.
Total figures: 4,943,855 cases of coronavirus confirmed with diagnostic test of active infection;
There have been 86,185 dead with positive test as of September 23.
The centers for the control and prevention of diseases, also referred to as CDC, from the US recommend to people between 18 and 49 years with health problems the administration of a third dose of reinforcement of the coreavirus of Pfizer-Biontech
At least within six months of the second dose, reports Reuters.
At the same time, it recommends the administration of this dose of reinforcement to people from the residences of the third age of more than 65 years, also at six months of the last puncture.
The European Medicine Agency (EMA) has announced that it expects to decide on the need for a dose of reinforcement of the Pfizer Coronavirus’ vaccine “at the beginning of October”, although it stressed that all the vaccines authorized in the European Union (EU)
“They provide a strong protection” against the Covid-19.
At a virtual press conference, Marco Cavaleri, head of vaccine strategy, stressed that EMA expects to end “early October” its evaluation of an application presented by Pfizer and Biontech pharmaceutics to authorize the use of a reinforcement dose of
Its vaccine, a third injection six months after the second, more than 16 years, reports EFE.
The COVID-19 may seem over time a cold because the viruses tend to weaken as they extend among the population, according to Sarah Gilbert, the scientist at the University of Oxford who developed the AstraZeneca vaccine.
“Normally we see that viruses become less virulent while circulating more easily and there are no reasons to think that we have a more virulent version of SARS-COV-2,” Gilbert said last night at a Web seminar of the Royal Society of Medicine, reports EFE.
.
According to her, the population will develop immunity as it happens with other seasonal coronavirus, which cause colds.
Pregnant women who contract Coronavirus have more risk of suffering from severe Covid, preeclampsia and premature birth.
They are a priority group to vaccinate and there is increasing evidence that the vaccine is completely secure for them.
In addition, a study published in the ‘American Journal of Obtetrics & Gynecology’ ensures that women who receive mRNA vaccines against COVID-19 -Pfizer and modern – during pregnancy transmit high levels of antibodies to their babies, with which
They are born with immunity against the Covid-19.
The study indicates that in 100% of the cases studied, the baby was born with protective antibodies.
The researchers analyzed blood samples from the umbilical cord and found neutralizing viral protein antibodies, anti-S.
The transfer was made vertically from vaccination, surpassing antibodies that are created during natural infection.
Despite being a small sample, Dr. Jennifer L. Lighter, Principal Author of the Study and Associated Professor in the Department of Pediatrics, Hassenfeld Children Hospital Epidemiology at NYU Lagone, considers very “encouraging that levels of neonatal antibodies are Altosi
Women are vaccinated. ”
“The high levels of transfer of transplacent antibodies are not surprising, it is consistent with what we see with other vaccines, our findings are added to an increasing list of important reasons why women receiving the Vaccine Covid should be recommended
-19 During pregnancy for the additional benefit that your newborn receives crucial protection, “adds Dr. Lighter.
The World Health Organization (WHO) updated its medication guide on Friday to combat coronavirus and included the combination of Casairivimab and IMDEVIMAD for the treatment of non-severe COVID-19 patients and at risk of hospitalization, but requested equitable access
to them.
The two drugs are produced by the American company Regeneron and were those who used the then US President, Donald Trump, when Covid-19 contracted, although a treatment with them, without sanitary covers, can cost thousands of dollars.
Given the high cost and low availability of this combined therapy, WHO asked Regeneron to lower prices and distribute it equitably in all regions, especially in low and middle income countries, and transfer technology to allow the manufacture of
Biosimilar versions so that all patients who may need this treatment have access to it.
[Read the full information here].
